Clinical trials: Hypertensive Heart Disease
Heart Failure
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.
- Trial name
- NCT00775840
- Testing
- Candesartan
- Where
- 37 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Takeda
Hypertension
A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.
Comparison of the safety and efficacy of the combination of amlodipine/Benazepril to amlodipine monotherapy in patients with non-essential hypertension, not controlled on amlodipine alone.
- Trial name
- NCT00171366
- Testing
- amlodipine/benazepril
- Where
- United States
- Volunteers
- 1,422 people
- Sponsor
- Novartis
Hypertension
Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension
This study compares the effect of Adalat LA to Coracten on drug levels as well as changes in blood pressure and heart rate in fed hypertensive subjects.
- Trial name
- NCT00672113
- Testing
- Adalat (Nifedipine, BAYA1040), Coracten
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Bayer
Essential Hypertension With Stable Angina and Dyslipidemia
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.
- Trial name
- ALIVE (NCT02400775)
- Testing
- Azilsartan
- Where
- Japan
- Sponsor
- Takeda
Hypertension
An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes
To describe the effectiveness of angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium channel blocker single pill combination on systolic blood pressure (SBP) lowering in hypertensive patients with elevated…
- Trial name
- HARVEST-TR (NCT02298556)
- Where
- 23 sites in Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Abbott
Diastolic Dysfunction, Hypertension
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
Patients who have had high blood pressure for a long time may have diastolic dysfunction. Diastolic Dysfunction is when your heart has difficulty filling and emptying, and relaxing adequately.
- Trial name
- NCT00170924
- Testing
- Valsartan
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Novartis
Hypertension
Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)
This study was designed to evaluate the pharmacodynamics of a bolus dosing regimen of clevidipine, a vascular-selective L-type calcium channel antagonist, for the management of blood pressure in cardiac surgery patients, as well…
- Trial name
- SPRINT (NCT00799604)
- Testing
- clevidipine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- The Medicines Company
Hypertrophy, Left Ventricular
The CLEVER Study - Coreg And Left Ventricular Mass Regression
This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition…
- Trial name
- NCT00108082
- Testing
- carvedilol MR, atenolol, lisinopril
- Where
- 78 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Heart Failure With Preserved Ejection Fraction (HFpEF), Hypertension
Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System
This study is a prospective, double blind, self-controlled, randomized, cross-over study to evaluate the feasibility, efficacy, and safety of treating patients with Heart Failure with preserved Ejection Fraction (HFpEF)…
- Trial name
- RelieveHFpEFII (NCT06036186)
- Testing
- BaroPacing treatment, Standard treatment
- Where
- 3 sites in India
- Volunteers
- 16 people
- Sponsor
- BaroPace Inc.
Hypertension
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
This is a multicentre, randomized, open-label parallel trial to demonstrate the superiority and/or non-inferiority of bisoprolol on metoprolol succinate sustained-release (SR) tablet in subjects with mild to moderate primary…
- Trial name
- CREATIVE (NCT01508325)
- Testing
- Bisoprolol, Metoprolol
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
Hypertension, Coronary Artery Disease
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease
This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery…
- Trial name
- NCT00673075
- Testing
- Nebivolol, Carvedilol
- Where
- 34 sites in United States
- Volunteers
- 39 people
- Sponsor
- Forest Laboratories
Bradycardia
Impact of Allometric Pacing Rate on Ventricular Diastolic Function and Cerebral Blood Flow in Hypertensive Patients With Sinus Node Dysfunction
The study is a prospective, randomized controlled study in hypertensive patients with a bradycardia indications for pacing therapy and a plan to receive dual-chamber pacemaker.
- Trial name
- NCT07589452
- Testing
- Personalized lower rate pacing, Standard lower rate pacing
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypertension
Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management
To assess the pattern of hypertension in the population in terms of presence of additional risk factors (ARF) and cardiovascular risk stratification.
- Trial name
- NCT00709787
- Testing
- Usual Care
- Where
- 2 sites in Croatia, Czechia
- Volunteers
- 899 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.
- Trial name
- NCT00386139
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 881 people
- Sponsor
- Novartis
Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)
The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart.
- Trial name
- NCT00338260
- Testing
- MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years
- Volunteers
- 496 people
- Sponsor
- Organon and Co
Heart Failure
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in their heart failure signs and symptoms and…
- Trial name
- NCT00219011
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 280 people
- Sponsor
- Novartis